The Therapeutics Initiative presents critically appraised summary evidence primarily from controlled drug trials. Such evidence applies to patients similar to those involved in the trails, and may not be generalizable to every patient. We are committed to evaluate the effectiveness of our educational activities using the Pharmacare/PharmaNet databases without identifying individual physicians, pharmacies or patients. The Therapeutics Initiative is funded by the BC Ministry of Health through a 5-year grant to the University of BC. The Therapeutics Initiative provides evidence based advice about drug therapy, and is not responsible for formulating or adjudicating provincial drug policies. 

Click here to download a printable version of this Therapeutics Letter in Adobe Acrobat PDF format (86 KB).

Therapeutics Letter, issue 48, April - June 2003

Do Statins have a Role in Primary Prevention? 

Click here to go to a comment regarding Therapeutics Letter #48, posted on October 16, 2003 about the evidence of benefit for primary prevention in women.

Two important questions regarding statin therapy are:

Three new randomized controlled trials1-3, which help answer the first question and one trial providing insight into the second question have been published since our last Letter on lipid lowering therapy (#42). This Letter addresses the first question and the next Letter (#49) will address the second.
Estimating the overall health impact of statins in primary prevention requires balancing possible benefits and possible harms. In this Letter benefit is estimated by combining two cardiovascular serious adverse events known to be reduced by statins in secondary prevention trials: total myocardial infarction (fatal and non-fatal)5 and total stroke (fatal and non-fatal).6 The balance between benefit and harm (overall health impact) is estimated by total mortality and total serious adverse events. Serious adverse events include any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of hospitalization, or results in persistent or significant disability.

Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)1

PROSPER studied the effect of pravastatin compared to placebo in two older populations of patients: 56% primary prevention (no past or symptomatic cardiovascular disease) and 44% secondary prevention (past or symptomatic cardiovascular disease) (Table 1). Pravastatin did not reduce total myocardial infarction or total stroke in the primary prevention population, RR 0.94 [0.78 – 1.14], but did so in the secondary prevention population, RR 0.80 [0.68 – 0.94], ARR 4.3%, NNT 23 for 3.2 years. Measures of overall health impact in the combined populations, total mortality and total serious adverse events, were unchanged by pravastatin as compared to placebo, RR 0.98 [0.84 – 1.14] and 1.01 [0.96 – 1.06], respectively.

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)2
ALLHAT-LLT was designed to determine whether pravastatin compared with usual care reduces all-cause mortality in older, moderately hypercholesterolemic, hypertensive patients with at least 1 additional coronary heart disease risk factor. The published data is for the whole population, 86% of which was primary prevention. Pravastatin did not reduce total myocardial infarction and total stroke, RR 0.91 [0.82 – 1.01]. Pravastatin also did not reduce total mortality, RR 0.99 [0.89 – 1.09]. Total serious adverse events were not reported.

Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA)3
ASCOT-LLA was designed to assess the benefits of atorvastatin versus placebo in hypertensive patients with average or lower-than-average cholesterol concentrations and at least 3 other cardiovascular risk factors. The published data is for the whole population, 82% of which was primary prevention. The trial was originally planned for 5 years, but was stopped after a median follow-up of 3.3 years because of a significant reduction in cardiac events. Atorvastatin reduced total myocardial infarction and total stroke, RR 0.82 [0.70 – 0.96], ARR 1.2%, NNT 83. Total mortality was not significantly reduced, RR 0.87 [0.71 – 1.05]. The trial report stated that total serious adverse events “did not differ between patients assigned atorvastatin or placebo”, but the actual numbers of serious adverse events were not given.

What is the overall health impact when statins are prescribed for primary prevention?
To attempt to answer this question we combined the data from the 5 mostly primary prevention trials, the 3 above plus 2 published earlier7,8 (Table 1 & Table 2). Note that these calculations reflect a population that is 84% primary prevention and 16% secondary prevention. In the pooled data the statins reduced the cardiovascular measures, total myocardial infarction and total stroke, by 1.4% as compared to control. This value indicates that 71 mostly primary prevention patients would have to be treated for 3 to 5 years to prevent one such event. This can be compared with the same pooled outcome in 4 large secondary prevention statin trials, ARR 4.8%, NNT 21 for 5 years. (Letter #42, HPS4)
In the 2 trials where serious adverse events are reported, the 1.8% absolute reduction in myocardial infarction and stroke should be reflected by a similar absolute reduction in total serious adverse events; myocardial infarction and stroke are, by definition, serious adverse events. However, this is not the case; serious adverse events are similar in the statin group, 44.2%, and the control group, 43.9% (Table 2). This is consistent with the possibility that unrecognized serious adverse events are increased by statin therapy and that the magnitude of the increase is similar to the magnitude of the reduction in cardiovascular serious adverse events in these populations. This hypothesis needs to be tested by analysis of total serious adverse event data in both past and future statin trials. Serious adverse event data is available to trial authors, drug companies and drug regulators. The other measure of overall impact, total mortality, is available in all 5 trials and is not reduced by statin therapy (Table 2).


RR = Relative Risk. CI = Confidence Interval. ARR = Absolute Risk Reduction.
NNT = Number Needed to Treat to prevent one event.

Table 1:  Characteristics of the 5 major statin primary prevention trials

Trial Drug Name Trade Name Dose mg/day N Average age (yr) % male % Primary Prevention Baseline mean Tchol. (mmol/L) D mean Tchol*
PROSPER1 pravastatin Pravachol©, generic 40 5,804 75 48 56 5.7 -19
ALLHAT-LLT2 pravastatin Pravachol©, generic 40 10,355 66 51 86 5.8 -11
ASCOT-LLA3 atorvastatin Lipitor© 10 10,305 63 81 82 5.5 -24
AFCAPS7 lovastatin Mevacor©, generic 20-40 6,605 58 85 100 5.7 -19
WOSCOP8 pravastatin Pravachol©, generic 40 6,595 55 100 92 7.0 -20

* % reduction in the statin group minus the control group after 1 to 2 years of therapy.

N = total number of patients in trial

D = change

Table 2: Meta-analysis of major outcomes from the 5 statin primary prevention trials

Outcome Statin Control RR [95% CI] ARR NNT (3-5 yr)
5 trials 2 trials* 5 trials 2 trials* 5 trials 2 trials* 5 trials 2 trials* 5 trials 2 trials*
Total mortality 6.6 6.1 6.9 6.2 0.95 [0.88-1.02] 0.99 [0.87-1.14]        
Total MI and stroke 7.3 8.0 8.7 9.8 0.84 [0.78-0.90] 0.82 [0.73-0.92] 1.4 1.8 71 56
Total SAEs*   44.2   43.9   1.01 [0.97-1.05]        


MI = Myocardial Infarction

SAEs = Serious Adverse Events

This Therapeutics Letter contains an assessment and synthesis of publications up to May 2003. We attempt to maintain the accuracy of the information contained in the Therapeutics Letter by extensive literature searches and verification by both the authors and the editorial board. In addition this Therapeutics Letter was submitted for review to 45 experts and primary care physicians in order to correct any identified shortcomings or inaccuracies and to ensure that the information is concise and relevant to clinicians.

A question to us about Letter #48: What is the evidence of benefit for primary prevention in women?

There were 10,990 women in the primary prevention trials (28% of the total). Only coronary events were reported for women, but when these were pooled they were not reduced by statin therapy, RR 0.98 [0.85-1.12]. Thus the coronary benefit in primary prevention trials appears to be limited to men, RR 0.74 [0.68-0.81], ARR 2.0%, NNT 50 for 3 to 5 years.


  1. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-1630.

  2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.

  3. Sever PS, Dhalof B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-1158.

  4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.

  5. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-213.

  6. Crouse JR 3rd., Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. [erratum appears in Atherosclerosis 1998;140:193-4]. Atherosclerosis 1998;138:11-24.

  7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-1622.

  8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.

Please send feedback!

Back to Therapeutics Letter.

Back to the Therapeutics Initiative Home Page.

©Therapeutics Initiative. Last updated: October 16, 2003.